nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Infestation—Imiquimod—skin cancer	0.00612	0.00612	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Vismodegib—skin cancer	0.00606	0.00606	CcSEcCtD
Apraclonidine—Dry eye—Temozolomide—skin cancer	0.00606	0.00606	CcSEcCtD
Apraclonidine—Eye disorder—Vemurafenib—skin cancer	0.00602	0.00602	CcSEcCtD
Apraclonidine—Dermatitis contact—Fluorouracil—skin cancer	0.00597	0.00597	CcSEcCtD
Apraclonidine—Conjunctivitis—Imiquimod—skin cancer	0.00595	0.00595	CcSEcCtD
Apraclonidine—Abdominal pain—Vismodegib—skin cancer	0.00586	0.00586	CcSEcCtD
Apraclonidine—Angiopathy—Vemurafenib—skin cancer	0.00585	0.00585	CcSEcCtD
Apraclonidine—Mediastinal disorder—Vemurafenib—skin cancer	0.00581	0.00581	CcSEcCtD
Apraclonidine—Abnormal vision—Temozolomide—skin cancer	0.00572	0.00572	CcSEcCtD
Apraclonidine—Photophobia—Fluorouracil—skin cancer	0.00568	0.00568	CcSEcCtD
Apraclonidine—Erythema—Vemurafenib—skin cancer	0.00561	0.00561	CcSEcCtD
Apraclonidine—Rhinitis—Imiquimod—skin cancer	0.00551	0.00551	CcSEcCtD
Apraclonidine—Haemorrhage—Imiquimod—skin cancer	0.0055	0.0055	CcSEcCtD
Apraclonidine—Dysgeusia—Vemurafenib—skin cancer	0.0055	0.0055	CcSEcCtD
Apraclonidine—Pharyngitis—Imiquimod—skin cancer	0.00546	0.00546	CcSEcCtD
Apraclonidine—Rhinorrhoea—Docetaxel—skin cancer	0.00539	0.00539	CcSEcCtD
Apraclonidine—Asthenia—Vismodegib—skin cancer	0.00532	0.00532	CcSEcCtD
Apraclonidine—Visual impairment—Imiquimod—skin cancer	0.0053	0.0053	CcSEcCtD
Apraclonidine—Eye pain—Temozolomide—skin cancer	0.00527	0.00527	CcSEcCtD
Apraclonidine—Pruritus—Vismodegib—skin cancer	0.00524	0.00524	CcSEcCtD
Apraclonidine—Eye disorder—Imiquimod—skin cancer	0.00514	0.00514	CcSEcCtD
Apraclonidine—Eye irritation—Docetaxel—skin cancer	0.00511	0.00511	CcSEcCtD
Apraclonidine—Diarrhoea—Vismodegib—skin cancer	0.00507	0.00507	CcSEcCtD
Apraclonidine—Angiopathy—Imiquimod—skin cancer	0.00499	0.00499	CcSEcCtD
Apraclonidine—Mediastinal disorder—Imiquimod—skin cancer	0.00495	0.00495	CcSEcCtD
Apraclonidine—Arrhythmia—Imiquimod—skin cancer	0.00491	0.00491	CcSEcCtD
Apraclonidine—Mental disorder—Imiquimod—skin cancer	0.00482	0.00482	CcSEcCtD
Apraclonidine—Erythema—Imiquimod—skin cancer	0.00479	0.00479	CcSEcCtD
Apraclonidine—Myalgia—Vemurafenib—skin cancer	0.00478	0.00478	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00474	0.00474	CcSEcCtD
Apraclonidine—Lacrimation increased—Docetaxel—skin cancer	0.00473	0.00473	CcSEcCtD
Apraclonidine—Vomiting—Vismodegib—skin cancer	0.00471	0.00471	CcSEcCtD
Apraclonidine—Dermatitis—Vismodegib—skin cancer	0.00467	0.00467	CcSEcCtD
Apraclonidine—Face oedema—Temozolomide—skin cancer	0.0046	0.0046	CcSEcCtD
Apraclonidine—Infection—Vemurafenib—skin cancer	0.00455	0.00455	CcSEcCtD
Apraclonidine—Inflammation—Docetaxel—skin cancer	0.0045	0.0045	CcSEcCtD
Apraclonidine—Nervous system disorder—Vemurafenib—skin cancer	0.00449	0.00449	CcSEcCtD
Apraclonidine—Skin disorder—Vemurafenib—skin cancer	0.00445	0.00445	CcSEcCtD
Apraclonidine—Ill-defined disorder—Imiquimod—skin cancer	0.00444	0.00444	CcSEcCtD
Apraclonidine—Nausea—Vismodegib—skin cancer	0.0044	0.0044	CcSEcCtD
Apraclonidine—Malaise—Imiquimod—skin cancer	0.00432	0.00432	CcSEcCtD
Apraclonidine—Syncope—Imiquimod—skin cancer	0.00429	0.00429	CcSEcCtD
Apraclonidine—Palpitations—Imiquimod—skin cancer	0.00423	0.00423	CcSEcCtD
Apraclonidine—Irritability—Fluorouracil—skin cancer	0.00419	0.00419	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00417	0.00417	CcSEcCtD
Apraclonidine—Myalgia—Imiquimod—skin cancer	0.00407	0.00407	CcSEcCtD
Apraclonidine—Chest pain—Imiquimod—skin cancer	0.00407	0.00407	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00405	0.00405	CcSEcCtD
Apraclonidine—Discomfort—Imiquimod—skin cancer	0.00403	0.00403	CcSEcCtD
Apraclonidine—Dry mouth—Imiquimod—skin cancer	0.00398	0.00398	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00395	0.00395	CcSEcCtD
Apraclonidine—Fatigue—Vemurafenib—skin cancer	0.00395	0.00395	CcSEcCtD
Apraclonidine—Nasopharyngitis—Fluorouracil—skin cancer	0.00392	0.00392	CcSEcCtD
Apraclonidine—Constipation—Vemurafenib—skin cancer	0.00392	0.00392	CcSEcCtD
Apraclonidine—Oedema—Imiquimod—skin cancer	0.00391	0.00391	CcSEcCtD
Apraclonidine—Haemorrhage—Bleomycin—skin cancer	0.00391	0.00391	CcSEcCtD
Apraclonidine—Infection—Imiquimod—skin cancer	0.00388	0.00388	CcSEcCtD
Apraclonidine—Nervous system disorder—Imiquimod—skin cancer	0.00383	0.00383	CcSEcCtD
Apraclonidine—Skin disorder—Imiquimod—skin cancer	0.00379	0.00379	CcSEcCtD
Apraclonidine—Infestation NOS—Temozolomide—skin cancer	0.00367	0.00367	CcSEcCtD
Apraclonidine—Infestation—Temozolomide—skin cancer	0.00367	0.00367	CcSEcCtD
Apraclonidine—Pharyngitis—Dactinomycin—skin cancer	0.00362	0.00362	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00356	0.00356	CcSEcCtD
Apraclonidine—Insomnia—Imiquimod—skin cancer	0.00353	0.00353	CcSEcCtD
Apraclonidine—Paraesthesia—Imiquimod—skin cancer	0.00351	0.00351	CcSEcCtD
Apraclonidine—Dyspnoea—Imiquimod—skin cancer	0.00348	0.00348	CcSEcCtD
Apraclonidine—Somnolence—Imiquimod—skin cancer	0.00347	0.00347	CcSEcCtD
Apraclonidine—Erythema—Bleomycin—skin cancer	0.0034	0.0034	CcSEcCtD
Apraclonidine—Infestation NOS—Fluorouracil—skin cancer	0.00338	0.00338	CcSEcCtD
Apraclonidine—Infestation—Fluorouracil—skin cancer	0.00338	0.00338	CcSEcCtD
Apraclonidine—Hypersensitivity—Vemurafenib—skin cancer	0.00337	0.00337	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00337	0.00337	CcSEcCtD
Apraclonidine—Fatigue—Imiquimod—skin cancer	0.00337	0.00337	CcSEcCtD
Apraclonidine—Pain—Imiquimod—skin cancer	0.00334	0.00334	CcSEcCtD
Apraclonidine—Haemorrhage—Temozolomide—skin cancer	0.00329	0.00329	CcSEcCtD
Apraclonidine—Conjunctivitis—Fluorouracil—skin cancer	0.00329	0.00329	CcSEcCtD
Apraclonidine—Asthenia—Vemurafenib—skin cancer	0.00329	0.00329	CcSEcCtD
Apraclonidine—Pharyngitis—Temozolomide—skin cancer	0.00327	0.00327	CcSEcCtD
Apraclonidine—Oedema peripheral—Temozolomide—skin cancer	0.00325	0.00325	CcSEcCtD
Apraclonidine—Pruritus—Vemurafenib—skin cancer	0.00324	0.00324	CcSEcCtD
Apraclonidine—Feeling abnormal—Imiquimod—skin cancer	0.00322	0.00322	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Imiquimod—skin cancer	0.00319	0.00319	CcSEcCtD
Apraclonidine—Visual impairment—Temozolomide—skin cancer	0.00317	0.00317	CcSEcCtD
Apraclonidine—Erythema—Dactinomycin—skin cancer	0.00317	0.00317	CcSEcCtD
Apraclonidine—Ill-defined disorder—Bleomycin—skin cancer	0.00315	0.00315	CcSEcCtD
Apraclonidine—Diarrhoea—Vemurafenib—skin cancer	0.00313	0.00313	CcSEcCtD
Apraclonidine—Abdominal pain—Imiquimod—skin cancer	0.00309	0.00309	CcSEcCtD
Apraclonidine—Eye disorder—Temozolomide—skin cancer	0.00308	0.00308	CcSEcCtD
Apraclonidine—Malaise—Bleomycin—skin cancer	0.00307	0.00307	CcSEcCtD
Apraclonidine—Rhinitis—Fluorouracil—skin cancer	0.00304	0.00304	CcSEcCtD
Apraclonidine—Haemorrhage—Fluorouracil—skin cancer	0.00304	0.00304	CcSEcCtD
Apraclonidine—Dizziness—Vemurafenib—skin cancer	0.00303	0.00303	CcSEcCtD
Apraclonidine—Pharyngitis—Fluorouracil—skin cancer	0.00301	0.00301	CcSEcCtD
Apraclonidine—Angiopathy—Temozolomide—skin cancer	0.00299	0.00299	CcSEcCtD
Apraclonidine—Mediastinal disorder—Temozolomide—skin cancer	0.00297	0.00297	CcSEcCtD
Apraclonidine—Ill-defined disorder—Dactinomycin—skin cancer	0.00294	0.00294	CcSEcCtD
Apraclonidine—Vomiting—Vemurafenib—skin cancer	0.00291	0.00291	CcSEcCtD
Apraclonidine—Chest pain—Bleomycin—skin cancer	0.00289	0.00289	CcSEcCtD
Apraclonidine—Myalgia—Bleomycin—skin cancer	0.00289	0.00289	CcSEcCtD
Apraclonidine—Mental disorder—Temozolomide—skin cancer	0.00289	0.00289	CcSEcCtD
Apraclonidine—Dermatitis—Vemurafenib—skin cancer	0.00288	0.00288	CcSEcCtD
Apraclonidine—Hypersensitivity—Imiquimod—skin cancer	0.00288	0.00288	CcSEcCtD
Apraclonidine—Headache—Vemurafenib—skin cancer	0.00287	0.00287	CcSEcCtD
Apraclonidine—Erythema—Temozolomide—skin cancer	0.00287	0.00287	CcSEcCtD
Apraclonidine—Discomfort—Bleomycin—skin cancer	0.00286	0.00286	CcSEcCtD
Apraclonidine—Malaise—Dactinomycin—skin cancer	0.00286	0.00286	CcSEcCtD
Apraclonidine—Nasopharyngitis—Docetaxel—skin cancer	0.00283	0.00283	CcSEcCtD
Apraclonidine—Dysgeusia—Temozolomide—skin cancer	0.00281	0.00281	CcSEcCtD
Apraclonidine—Asthenia—Imiquimod—skin cancer	0.0028	0.0028	CcSEcCtD
Apraclonidine—Oedema—Bleomycin—skin cancer	0.00277	0.00277	CcSEcCtD
Apraclonidine—Pruritus—Imiquimod—skin cancer	0.00276	0.00276	CcSEcCtD
Apraclonidine—Infection—Bleomycin—skin cancer	0.00276	0.00276	CcSEcCtD
Apraclonidine—Nausea—Vemurafenib—skin cancer	0.00272	0.00272	CcSEcCtD
Apraclonidine—Arrhythmia—Fluorouracil—skin cancer	0.00271	0.00271	CcSEcCtD
Apraclonidine—Vision blurred—Temozolomide—skin cancer	0.0027	0.0027	CcSEcCtD
Apraclonidine—Myalgia—Dactinomycin—skin cancer	0.0027	0.0027	CcSEcCtD
Apraclonidine—Diarrhoea—Imiquimod—skin cancer	0.00267	0.00267	CcSEcCtD
Apraclonidine—Discomfort—Dactinomycin—skin cancer	0.00267	0.00267	CcSEcCtD
Apraclonidine—Ill-defined disorder—Temozolomide—skin cancer	0.00266	0.00266	CcSEcCtD
Apraclonidine—Erythema—Fluorouracil—skin cancer	0.00264	0.00264	CcSEcCtD
Apraclonidine—Oedema—Dactinomycin—skin cancer	0.00259	0.00259	CcSEcCtD
Apraclonidine—Malaise—Temozolomide—skin cancer	0.00259	0.00259	CcSEcCtD
Apraclonidine—Dizziness—Imiquimod—skin cancer	0.00258	0.00258	CcSEcCtD
Apraclonidine—Infection—Dactinomycin—skin cancer	0.00257	0.00257	CcSEcCtD
Apraclonidine—Palpitations—Temozolomide—skin cancer	0.00253	0.00253	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00253	0.00253	CcSEcCtD
Apraclonidine—Paraesthesia—Bleomycin—skin cancer	0.00249	0.00249	CcSEcCtD
Apraclonidine—Vision blurred—Fluorouracil—skin cancer	0.00249	0.00249	CcSEcCtD
Apraclonidine—Vomiting—Imiquimod—skin cancer	0.00248	0.00248	CcSEcCtD
Apraclonidine—Dyspnoea—Bleomycin—skin cancer	0.00247	0.00247	CcSEcCtD
Apraclonidine—Dermatitis—Imiquimod—skin cancer	0.00246	0.00246	CcSEcCtD
Apraclonidine—Headache—Imiquimod—skin cancer	0.00245	0.00245	CcSEcCtD
Apraclonidine—Myalgia—Temozolomide—skin cancer	0.00244	0.00244	CcSEcCtD
Apraclonidine—Infestation NOS—Docetaxel—skin cancer	0.00244	0.00244	CcSEcCtD
Apraclonidine—Infestation—Docetaxel—skin cancer	0.00244	0.00244	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00242	0.00242	CcSEcCtD
Apraclonidine—Discomfort—Temozolomide—skin cancer	0.00241	0.00241	CcSEcCtD
Apraclonidine—Dry mouth—Temozolomide—skin cancer	0.00239	0.00239	CcSEcCtD
Apraclonidine—Pain—Bleomycin—skin cancer	0.00237	0.00237	CcSEcCtD
Apraclonidine—Conjunctivitis—Docetaxel—skin cancer	0.00237	0.00237	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00236	0.00236	CcSEcCtD
Apraclonidine—Oedema—Temozolomide—skin cancer	0.00234	0.00234	CcSEcCtD
Apraclonidine—Infection—Temozolomide—skin cancer	0.00233	0.00233	CcSEcCtD
Apraclonidine—Nausea—Imiquimod—skin cancer	0.00232	0.00232	CcSEcCtD
Apraclonidine—Nervous system disorder—Temozolomide—skin cancer	0.0023	0.0023	CcSEcCtD
Apraclonidine—Feeling abnormal—Bleomycin—skin cancer	0.00229	0.00229	CcSEcCtD
Apraclonidine—Skin disorder—Temozolomide—skin cancer	0.00227	0.00227	CcSEcCtD
Apraclonidine—Myalgia—Fluorouracil—skin cancer	0.00225	0.00225	CcSEcCtD
Apraclonidine—Chest pain—Fluorouracil—skin cancer	0.00225	0.00225	CcSEcCtD
Apraclonidine—Fatigue—Dactinomycin—skin cancer	0.00223	0.00223	CcSEcCtD
Apraclonidine—Discomfort—Fluorouracil—skin cancer	0.00222	0.00222	CcSEcCtD
Apraclonidine—Pain—Dactinomycin—skin cancer	0.00221	0.00221	CcSEcCtD
Apraclonidine—Rhinitis—Docetaxel—skin cancer	0.0022	0.0022	CcSEcCtD
Apraclonidine—Haemorrhage—Docetaxel—skin cancer	0.00219	0.00219	CcSEcCtD
Apraclonidine—Pharyngitis—Docetaxel—skin cancer	0.00217	0.00217	CcSEcCtD
Apraclonidine—Oedema peripheral—Docetaxel—skin cancer	0.00216	0.00216	CcSEcCtD
Apraclonidine—Oedema—Fluorouracil—skin cancer	0.00216	0.00216	CcSEcCtD
Apraclonidine—Infection—Fluorouracil—skin cancer	0.00214	0.00214	CcSEcCtD
Apraclonidine—Feeling abnormal—Dactinomycin—skin cancer	0.00213	0.00213	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00213	0.00213	CcSEcCtD
Apraclonidine—Insomnia—Temozolomide—skin cancer	0.00212	0.00212	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dactinomycin—skin cancer	0.00212	0.00212	CcSEcCtD
Apraclonidine—Nervous system disorder—Fluorouracil—skin cancer	0.00211	0.00211	CcSEcCtD
Apraclonidine—Visual impairment—Docetaxel—skin cancer	0.00211	0.00211	CcSEcCtD
Apraclonidine—Paraesthesia—Temozolomide—skin cancer	0.0021	0.0021	CcSEcCtD
Apraclonidine—Dyspnoea—Temozolomide—skin cancer	0.00209	0.00209	CcSEcCtD
Apraclonidine—Somnolence—Temozolomide—skin cancer	0.00208	0.00208	CcSEcCtD
Apraclonidine—Eye disorder—Docetaxel—skin cancer	0.00205	0.00205	CcSEcCtD
Apraclonidine—Abdominal pain—Dactinomycin—skin cancer	0.00205	0.00205	CcSEcCtD
Apraclonidine—Hypersensitivity—Bleomycin—skin cancer	0.00204	0.00204	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Temozolomide—skin cancer	0.00202	0.00202	CcSEcCtD
Apraclonidine—Fatigue—Temozolomide—skin cancer	0.00202	0.00202	CcSEcCtD
Apraclonidine—Pain—Temozolomide—skin cancer	0.002	0.002	CcSEcCtD
Apraclonidine—Constipation—Temozolomide—skin cancer	0.002	0.002	CcSEcCtD
Apraclonidine—Asthenia—Bleomycin—skin cancer	0.00199	0.00199	CcSEcCtD
Apraclonidine—Angiopathy—Docetaxel—skin cancer	0.00199	0.00199	CcSEcCtD
Apraclonidine—Mediastinal disorder—Docetaxel—skin cancer	0.00197	0.00197	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00196	0.00196	CcSEcCtD
Apraclonidine—Pruritus—Bleomycin—skin cancer	0.00196	0.00196	CcSEcCtD
Apraclonidine—Arrhythmia—Docetaxel—skin cancer	0.00196	0.00196	CcSEcCtD
Apraclonidine—Insomnia—Fluorouracil—skin cancer	0.00195	0.00195	CcSEcCtD
Apraclonidine—Paraesthesia—Fluorouracil—skin cancer	0.00194	0.00194	CcSEcCtD
Apraclonidine—Feeling abnormal—Temozolomide—skin cancer	0.00193	0.00193	CcSEcCtD
Apraclonidine—Dyspnoea—Fluorouracil—skin cancer	0.00192	0.00192	CcSEcCtD
Apraclonidine—Mental disorder—Docetaxel—skin cancer	0.00192	0.00192	CcSEcCtD
Apraclonidine—Somnolence—Fluorouracil—skin cancer	0.00192	0.00192	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Temozolomide—skin cancer	0.00191	0.00191	CcSEcCtD
Apraclonidine—Erythema—Docetaxel—skin cancer	0.00191	0.00191	CcSEcCtD
Apraclonidine—Hypersensitivity—Dactinomycin—skin cancer	0.00191	0.00191	CcSEcCtD
Apraclonidine—Dysgeusia—Docetaxel—skin cancer	0.00187	0.00187	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00186	0.00186	CcSEcCtD
Apraclonidine—Asthenia—Dactinomycin—skin cancer	0.00186	0.00186	CcSEcCtD
Apraclonidine—Abdominal pain—Temozolomide—skin cancer	0.00185	0.00185	CcSEcCtD
Apraclonidine—Pain—Fluorouracil—skin cancer	0.00184	0.00184	CcSEcCtD
Apraclonidine—Feeling abnormal—Fluorouracil—skin cancer	0.00178	0.00178	CcSEcCtD
Apraclonidine—Diarrhoea—Dactinomycin—skin cancer	0.00177	0.00177	CcSEcCtD
Apraclonidine—Vomiting—Bleomycin—skin cancer	0.00176	0.00176	CcSEcCtD
Apraclonidine—Dermatitis—Bleomycin—skin cancer	0.00175	0.00175	CcSEcCtD
Apraclonidine—Hypersensitivity—Temozolomide—skin cancer	0.00172	0.00172	CcSEcCtD
Apraclonidine—Syncope—Docetaxel—skin cancer	0.00171	0.00171	CcSEcCtD
Apraclonidine—Palpitations—Docetaxel—skin cancer	0.00169	0.00169	CcSEcCtD
Apraclonidine—Asthenia—Temozolomide—skin cancer	0.00168	0.00168	CcSEcCtD
Apraclonidine—Pruritus—Temozolomide—skin cancer	0.00166	0.00166	CcSEcCtD
Apraclonidine—Nausea—Bleomycin—skin cancer	0.00165	0.00165	CcSEcCtD
Apraclonidine—Vomiting—Dactinomycin—skin cancer	0.00165	0.00165	CcSEcCtD
Apraclonidine—Chest pain—Docetaxel—skin cancer	0.00162	0.00162	CcSEcCtD
Apraclonidine—Myalgia—Docetaxel—skin cancer	0.00162	0.00162	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00161	0.00161	CcSEcCtD
Apraclonidine—Diarrhoea—Temozolomide—skin cancer	0.0016	0.0016	CcSEcCtD
Apraclonidine—Hypersensitivity—Fluorouracil—skin cancer	0.00159	0.00159	CcSEcCtD
Apraclonidine—Dry mouth—Docetaxel—skin cancer	0.00159	0.00159	CcSEcCtD
Apraclonidine—Oedema—Docetaxel—skin cancer	0.00156	0.00156	CcSEcCtD
Apraclonidine—Dizziness—Temozolomide—skin cancer	0.00155	0.00155	CcSEcCtD
Apraclonidine—Infection—Docetaxel—skin cancer	0.00155	0.00155	CcSEcCtD
Apraclonidine—Nausea—Dactinomycin—skin cancer	0.00154	0.00154	CcSEcCtD
Apraclonidine—Nervous system disorder—Docetaxel—skin cancer	0.00153	0.00153	CcSEcCtD
Apraclonidine—Pruritus—Fluorouracil—skin cancer	0.00153	0.00153	CcSEcCtD
Apraclonidine—Skin disorder—Docetaxel—skin cancer	0.00151	0.00151	CcSEcCtD
Apraclonidine—Vomiting—Temozolomide—skin cancer	0.00149	0.00149	CcSEcCtD
Apraclonidine—Diarrhoea—Fluorouracil—skin cancer	0.00148	0.00148	CcSEcCtD
Apraclonidine—Dermatitis—Temozolomide—skin cancer	0.00147	0.00147	CcSEcCtD
Apraclonidine—Headache—Temozolomide—skin cancer	0.00147	0.00147	CcSEcCtD
Apraclonidine—Dizziness—Fluorouracil—skin cancer	0.00143	0.00143	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00142	0.00142	CcSEcCtD
Apraclonidine—Insomnia—Docetaxel—skin cancer	0.00141	0.00141	CcSEcCtD
Apraclonidine—Paraesthesia—Docetaxel—skin cancer	0.0014	0.0014	CcSEcCtD
Apraclonidine—Nausea—Temozolomide—skin cancer	0.00139	0.00139	CcSEcCtD
Apraclonidine—Dyspnoea—Docetaxel—skin cancer	0.00139	0.00139	CcSEcCtD
Apraclonidine—Somnolence—Docetaxel—skin cancer	0.00138	0.00138	CcSEcCtD
Apraclonidine—Vomiting—Fluorouracil—skin cancer	0.00137	0.00137	CcSEcCtD
Apraclonidine—Dermatitis—Fluorouracil—skin cancer	0.00136	0.00136	CcSEcCtD
Apraclonidine—Headache—Fluorouracil—skin cancer	0.00135	0.00135	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Docetaxel—skin cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Fatigue—Docetaxel—skin cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Pain—Docetaxel—skin cancer	0.00133	0.00133	CcSEcCtD
Apraclonidine—Constipation—Docetaxel—skin cancer	0.00133	0.00133	CcSEcCtD
Apraclonidine—Feeling abnormal—Docetaxel—skin cancer	0.00128	0.00128	CcSEcCtD
Apraclonidine—Nausea—Fluorouracil—skin cancer	0.00128	0.00128	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Docetaxel—skin cancer	0.00127	0.00127	CcSEcCtD
Apraclonidine—Abdominal pain—Docetaxel—skin cancer	0.00123	0.00123	CcSEcCtD
Apraclonidine—Hypersensitivity—Docetaxel—skin cancer	0.00115	0.00115	CcSEcCtD
Apraclonidine—Asthenia—Docetaxel—skin cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Pruritus—Docetaxel—skin cancer	0.0011	0.0011	CcSEcCtD
Apraclonidine—Diarrhoea—Docetaxel—skin cancer	0.00106	0.00106	CcSEcCtD
Apraclonidine—Dizziness—Docetaxel—skin cancer	0.00103	0.00103	CcSEcCtD
Apraclonidine—Vomiting—Docetaxel—skin cancer	0.00099	0.00099	CcSEcCtD
Apraclonidine—Dermatitis—Docetaxel—skin cancer	0.00098	0.00098	CcSEcCtD
Apraclonidine—Headache—Docetaxel—skin cancer	0.000975	0.000975	CcSEcCtD
Apraclonidine—Nausea—Docetaxel—skin cancer	0.000925	0.000925	CcSEcCtD
